Free Trial

Insider Selling: United Therapeutics Co. (NASDAQ:UTHR) Director Sells 255 Shares of Stock

United Therapeutics logo with Medical background

United Therapeutics Co. (NASDAQ:UTHR - Get Free Report) Director Nilda Mesa sold 255 shares of the stock in a transaction dated Monday, December 30th. The shares were sold at an average price of $355.77, for a total value of $90,721.35. Following the transaction, the director now directly owns 5,528 shares in the company, valued at approximately $1,966,696.56. This represents a 4.41 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Nilda Mesa also recently made the following trade(s):

  • On Friday, November 8th, Nilda Mesa sold 224 shares of United Therapeutics stock. The stock was sold at an average price of $412.28, for a total transaction of $92,350.72.

United Therapeutics Stock Performance

Shares of NASDAQ:UTHR traded down $4.80 during midday trading on Tuesday, reaching $352.84. 266,757 shares of the company's stock were exchanged, compared to its average volume of 443,397. The company's 50 day simple moving average is $370.41 and its two-hundred day simple moving average is $349.43. United Therapeutics Co. has a 12 month low of $208.62 and a 12 month high of $417.82. The firm has a market capitalization of $15.75 billion, a PE ratio of 15.50, a price-to-earnings-growth ratio of 1.05 and a beta of 0.55.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last released its quarterly earnings data on Wednesday, October 30th. The biotechnology company reported $6.39 earnings per share for the quarter, beating analysts' consensus estimates of $6.16 by $0.23. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The company had revenue of $748.90 million for the quarter, compared to the consensus estimate of $722.62 million. During the same period in the previous year, the business earned $5.38 earnings per share. The company's quarterly revenue was up 22.9% on a year-over-year basis. On average, research analysts anticipate that United Therapeutics Co. will post 25.22 earnings per share for the current year.

Institutional Trading of United Therapeutics

A number of large investors have recently bought and sold shares of the stock. Meiji Yasuda Asset Management Co Ltd. lifted its holdings in shares of United Therapeutics by 1.6% during the second quarter. Meiji Yasuda Asset Management Co Ltd. now owns 2,047 shares of the biotechnology company's stock valued at $652,000 after acquiring an additional 33 shares during the period. Toronto Dominion Bank lifted its holdings in United Therapeutics by 0.8% during the 2nd quarter. Toronto Dominion Bank now owns 4,525 shares of the biotechnology company's stock valued at $1,441,000 after purchasing an additional 37 shares during the last quarter. ClariVest Asset Management LLC boosted its position in United Therapeutics by 120.0% in the second quarter. ClariVest Asset Management LLC now owns 77 shares of the biotechnology company's stock valued at $25,000 after buying an additional 42 shares in the last quarter. Benjamin F. Edwards & Company Inc. grew its stake in United Therapeutics by 14.0% during the second quarter. Benjamin F. Edwards & Company Inc. now owns 343 shares of the biotechnology company's stock worth $109,000 after buying an additional 42 shares during the last quarter. Finally, First Citizens Bank & Trust Co. increased its holdings in shares of United Therapeutics by 1.8% during the third quarter. First Citizens Bank & Trust Co. now owns 2,681 shares of the biotechnology company's stock worth $961,000 after buying an additional 48 shares in the last quarter. 94.08% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several brokerages recently commented on UTHR. HC Wainwright lifted their target price on shares of United Therapeutics from $400.00 to $425.00 and gave the stock a "buy" rating in a report on Thursday, October 31st. Jefferies Financial Group lifted their price objective on United Therapeutics from $315.00 to $432.00 and gave the stock a "buy" rating in a research note on Monday, September 23rd. LADENBURG THALM/SH SH increased their target price on United Therapeutics from $319.00 to $344.00 and gave the company a "buy" rating in a research note on Thursday, October 31st. The Goldman Sachs Group lifted their price target on United Therapeutics from $243.00 to $302.00 and gave the stock a "neutral" rating in a research report on Friday, November 1st. Finally, Oppenheimer upped their price target on United Therapeutics from $575.00 to $600.00 and gave the stock an "outperform" rating in a report on Thursday, October 31st. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $370.86.

Check Out Our Latest Research Report on UTHR

About United Therapeutics

(Get Free Report)

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.

Read More

Insider Buying and Selling by Quarter for United Therapeutics (NASDAQ:UTHR)

Should You Invest $1,000 in United Therapeutics Right Now?

Before you consider United Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and United Therapeutics wasn't on the list.

While United Therapeutics currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

(Almost)  Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Crypto Boom 2025: Bitcoin’s Rise and Trump’s Impact on the Market
Goldman Sachs’ 2025 Market Outlook: Top 3 Stock Picks
7 Stocks to Benefit From Trump’s Tariffs in 2025

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines